Literature DB >> 21269937

Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats.

Zheng Wang1, Jia-Peng Xu, Yong-Chao Zheng, Wei Chen, Yong-Wei Sun, Zhi-Yong Wu, Meng Luo.   

Abstract

BACKGROUND: Hepatic fibrosis is a necessary step in the development of hepatic cirrhosis. In this study we used lentiviral vector-mediated transfection technology to evaluate the effect of peroxisome proliferator-activated receptor gamma (PPAR-gamma) on rat hepatic fibrosis.
METHODS: Hepatic fibrosis in rats was induced by CCl4 for 2 weeks (early fibrosis) and 8 weeks (sustained fibrosis). The rats were randomly divided into four groups: normal control, fibrosis, blank vector, and PPAR-gamma. They were infected with the recombinant lentiviral expression vector carrying the rat PPAR-gamma gene by portal vein injection. The liver of the rats was examined histologically and hydroxyproline was assessed. In vitro primary hepatic stellate cells (HSCs) were infected with the recombinant lentiviral expression vector carrying the rat PPAR-gamma gene. The status of HSC proliferation was measured by the MTT assay. The protein levels of PPAR-gamma, alpha-smooth muscle actin (alpha-SMA) and type I collagen expression were evaluated by the Western blotting method.
RESULTS: In vitro studies revealed that expression of PPAR-gamma inhibited expression of alpha-SMA and type I collagen in activated HSCs (P<0.01) as well as HSC proliferation (P<0.01). In vivo experiments indicated that in the early hepatic fibrosis group, the hydroxyproline content and the level of collagen I protein in the liver in the PPAR-gamma transfected group were not significantly different compared to the hepatic fibrosis group and the blank vector group; whereas the expressions of PPAR-gamma and alpha-SMA were different compared to the hepatic fibrosis group (P<0.01). In the sustained hepatic fibrosis group, there were significant differences in the hydroxyproline content and the expression of PPAR-gamma, alpha-SMA, and type I collagen between each group.
CONCLUSION: PPAR-gamma can inhibit HSC proliferation and hepatic fibrosis, and suppress alpha-SMA and type I collagen expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269937     DOI: 10.1016/s1499-3872(11)60009-x

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  18 in total

Review 1.  Potential effects of curcumin on peroxisome proliferator-activated receptor-γ in vitro and in vivo.

Authors:  Mohsen Mazidi; Ehsan Karimi; Mohsen Meydani; Majid Ghayour-Mobarhan; Gordon A Ferns
Journal:  World J Methodol       Date:  2016-03-26

Review 2.  Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.

Authors:  Feng Zhang; Desong Kong; Yin Lu; Shizhong Zheng
Journal:  Cell Mol Life Sci       Date:  2012-06-15       Impact factor: 9.261

3.  Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis.

Authors:  Fatima Safira Alatas; Toshiharu Matsuura; Antonius Hocky Pudjiadi; Stephanie Wijaya; Tomoaki Taguchi
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2020-07-03

4.  Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.

Authors:  Susanne Mende; Sigrid Schulte; Ingo Strack; Heike Hunt; Margarete Odenthal; Galyna Pryymachuck; Maria Quasdorff; Münevver Demir; Dirk Nierhoff; Hans-Peter Dienes; Tobias Goeser; Hans-Michael Steffen; Ulrich Töx
Journal:  Dig Dis Sci       Date:  2012-12-18       Impact factor: 3.199

Review 5.  Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: a putative synergy between retinoic acid and PPAR-gamma signalings.

Authors:  Concetta Panebianco; Jude A Oben; Manlio Vinciguerra; Valerio Pazienza
Journal:  Clin Exp Med       Date:  2016-09-21       Impact factor: 3.984

6.  Propolis alleviates concanavalin A-induced hepatitis by modulating cytokine secretion and inhibition of reactive oxygen species.

Authors:  Fatma Mounieb; Laila Ramadan; El-Sayed Akool; Amany Balah
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-31       Impact factor: 3.000

7.  Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.

Authors:  I Walter; U Schulz; M Vogelhuber; K Wiedmann; E Endlicher; F Klebl; R Andreesen; W Herr; L Ghibelli; C Hackl; R Wiest; A Reichle
Journal:  Med Oncol       Date:  2017-11-02       Impact factor: 3.064

Review 8.  The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

Authors:  Jingjing Li; Chuanyong Guo; Jianye Wu
Journal:  Drug Des Devel Ther       Date:  2021-06-18       Impact factor: 4.162

9.  A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions.

Authors:  Thomas Bertero; Katherine A Cottrill; Sofia Annis; Balkrishen Bhat; Bernadette R Gochuico; Juan C Osorio; Ivan Rosas; Kathleen J Haley; Kathleen E Corey; Raymond T Chung; B Nelson Chau; Stephen Y Chan
Journal:  Sci Rep       Date:  2015-12-15       Impact factor: 4.379

Review 10.  Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases.

Authors:  Ting Liu; Yu Zhou; Kwang Suk Ko; Heping Yang
Journal:  Mediators Inflamm       Date:  2015-10-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.